Black Diamond Therapeutics Inc. (BDTX) is a clinical-stage biopharmaceutical company that is focused on developing targeted therapies for patients with cancers caused by specific genetic mutations. The company's proprietary platform, called Mutation-Allostery-Pharmacology, or MAP, is designed to identify and target oncogenic driver mutations, which are mutations that are believed to be key drivers of cancer growth.
BDTX is developing a pipeline of novel therapeutics that target specific genetic alterations driving the growth of cancer. The company's lead candidate, BDTX-189, is a small molecule inhibitor of EGFR and HER2 exon 20 insertion mutations, which are found in a variety of solid tumor cancers. BDTX-189 is currently in Phase 1/2 clinical trials.
Here are some additional key highlights for BDTX:
As of September 30, 2021, BDTX reported total assets of $497.1 million and total liabilities of $75.3 million.
The company reported a net loss of $67.6 million for the nine months ended September 30, 2021, compared to a net loss of $36.6 million for the same period in 2020.
BDTX reported no revenue for the nine months ended September 30, 2021, compared to $0.5 million in revenue for the same period in 2020.
As of September 30, 2021, the company had cash, cash equivalents, and marketable securities of $499.9 million, which the company believes will be sufficient to fund its operations into 2024.
Overall, BDTX is a clinical-stage biopharmaceutical company with a proprietary platform focused on developing targeted therapies for patients with cancer caused by specific genetic mutations. The company's lead candidate, BDTX-189, is in Phase 1/2 clinical trials, and the company has a strong balance sheet with significant cash reserves to continue its research and development activities.
|
